Otsuka Holdings is to acquire the US firm Astex Pharmaceuticals for $8.50 per share, or around $886m, in a move that will expand the major diversified Japanese group's interests in both oncology and the CNS area in line with mid-term strategy.
Otsuka snaps up cancer/CNS venture Astex for $886m
Otsuka Holdings is to acquire the US firm Astex Pharmaceuticals for $8.50 per share, or around $886m, in a move that will expand the major diversified Japanese group's interests in both oncology and the CNS area in line with mid-term strategy.
More from Anticancer
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.